ARTICLE | Company News
Cubist, Illumigen deal
October 22, 2007 7:00 AM UTC
CBST received an exclusive option to acquire Illumigen. Illumigen received $4.7 million for the option and an additional $1 million for an IND-enabling study of IB657, an interferon replacement therap...